Severe Intraocular Infection

University Hospital, Strasbourg, France263 enrolled

Overview

The host-immune reaction to infection is essential for the comprehension of the disease and the development of new therapies. The aim of the study is to describe intraocular cytokines network in aqueous humor using multiplex immunoassay, during severe intraocular infection.

Study Type

OBSERVATIONAL

Enrollment

263

Conditions

Endophthalmitis

Interventions

Cytokines dosage in Aqueous humorBIOLOGICAL

Specify details not covered in associated Arm Description.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Post-operative endophthalmitis * Cataract Exclusion Criteria: * None

Locations (7)

Service d'Ophtalmologie, Hôpital Pasteur

Colmar, France

Service d'Ophtalmologie, Hôpital Général de Dijon

Dijon, France

Service d'Ophtalmologie, Hôpital Michallon

Grenoble, France

Service d'Ophtalmologie, Centre Hospitalier de Mulhouse

Mulhouse, France

Outcomes

Primary Outcomes

Intraocular cytokine network. Intraocular levels of 27 cytokines

Cytokines and chemokines levels in Aqueous humor (AqH) are measured with the Bio-Plex® Multiplex System human Cytokine 27-Plex Panel assay (Bio-Rad, Marne-la-Coquette, France). The immune mediators were classified in five categories: (a) proinflammatory mediators: (IL-6 and monocyte chemoattractant protein (MCP-1), (b) type 1 cytokines: IL-2, IL-12(p70), Interferon (IFN-γ), and tumor necrosis factor-α (TNF-α), (c) type 2 cytokines: IL-4, IL-10 and IL-13, (d) T-regulatory cytokine: IL-10 and (e) Th-17 cytokine: IL-17. The cytokine and chemokine assay plate layout consisted of a standard series in duplicate (1 to 32 000 pg/ml), four blank wells and 20 μl duplicates of pooled AqH samples, diluted to 50 μl with BioPlex mouse serum diluent. The BioPlex® method was performed as recommended by the manufacturer and previously published studies. Data were analyzed with Bio-Plex Manager software® V 1.1 (Bio-Rad).

Time frame: Once in the 24 hours following the admission

Secondary Outcomes

Visual acuity

E Snellen Conversion in LogMAR unit

Time frame: Once in the 24 hours following the admission, then 3 months, 6 months and 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.